News headlines about Opko Health (NASDAQ:OPK) have trended somewhat positive on Saturday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Opko Health earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.0751045818295 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media stories that may have effected Accern’s analysis:
- Short Interest in Opko Health, Inc. (NASDAQ:OPK) Drops By 1.7% (americanbankingnews.com)
- Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Buys 39,000 Shares (americanbankingnews.com)
- Billionaire Phillip Frost defends his biotech firm on ‘Mad Money’ (finance.yahoo.com)
- OPKO Health (OPK) Posts Narrower-than-Estimated Loss in Q2 (finance.yahoo.com)
- Phillip Md Et Al Frost Purchases 18,000 Shares of Opko Health, Inc. (NASDAQ:OPK) Stock (americanbankingnews.com)
A number of equities research analysts recently issued reports on the stock. Zacks Investment Research cut shares of Opko Health from a “buy” rating to a “hold” rating in a research report on Saturday. Jefferies Group LLC reiterated a “hold” rating and set a $6.50 target price (down previously from $6.80) on shares of Opko Health in a research report on Thursday. BidaskClub cut shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Barrington Research increased their target price on shares of Opko Health to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 18th. Finally, Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $19.50 target price on shares of Opko Health in a research report on Friday, June 16th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $14.61.
Shares of Opko Health (NASDAQ OPK) opened at 6.24 on Friday. The firm’s market cap is $3.49 billion. Opko Health has a 52-week low of $5.99 and a 52-week high of $12.15. The firm has a 50-day moving average of $6.38 and a 200 day moving average of $7.28.
Opko Health (NASDAQ:OPK) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. Opko Health had a negative return on equity of 3.67% and a negative net margin of 6.52%. The company had revenue of $314.20 million for the quarter, compared to analysts’ expectations of $322.64 million. During the same period last year, the business earned $0.02 EPS. Opko Health’s quarterly revenue was down 12.0% compared to the same quarter last year. On average, equities analysts predict that Opko Health will post ($0.20) earnings per share for the current year.
In related news, Director Richard A. Lerner acquired 10,000 shares of the company’s stock in a transaction on Monday, June 5th. The shares were acquired at an average cost of $6.31 per share, for a total transaction of $63,100.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Phillip Md Et Al Frost acquired 5,000 shares of the company’s stock in a transaction on Tuesday, August 8th. The shares were bought at an average price of $6.05 per share, for a total transaction of $30,250.00. Following the completion of the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $18,567,153.55. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 1,631,000 shares of company stock worth $10,394,917. 40.19% of the stock is owned by company insiders.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
What are top analysts saying about Opko Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Opko Health Inc. and related companies.